Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2026 08:00 ET | Source: Curanex Pharmaceuticals Inc

Curanex Provides Operational Update on Key Regulatory Milestones

Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX)...
October 22, 2025 07:00 ET | Source: Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement

Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and...
September 12, 2025 14:46 ET | Source: Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters

Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering...
August 27, 2025 17:00 ET | Source: Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering

Jericho, New York, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and...
August 26, 2025 07:30 ET | Source: Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering

Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and...